SR One

SR One is an independent, transatlantic venture capital firm focused on biotechnology. It partners with founders and entrepreneurs to build companies developing new medicines, working across the life sciences domain with particular attention to oncology, immunology, cardiometabolic disease, infectious disease and rare diseases.

The firm operates a "back-and-build" model, supporting entrepreneurs with human, intellectual and financial resources rather than capital alone, with the stated aim of advancing innovative science toward medicines. Its stated investment criteria emphasise companies with strong fundamentals, defined development pathways and novel approaches to addressing disease. In sector terms, the firm works across biotechnology and pharmaceuticals, spanning disease biology and drug development.

SR One's geographic model is transatlantic. The investing team is based on the West Coast of the United States and in London, United Kingdom - key biotechnology hubs - with the stated purpose of supporting portfolio companies in real time. The firm describes its approach as combining continuity of experience with regional expertise, drawing on access to human, intellectual and financial resources to back and build companies alongside their founders.